Z Squared Inc. annual report, FY2023

Coeptis Therapeutics Holdings, Inc. — FY 2023 Form 10-K

Filing identity: The supplied filing is for Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), not Z Squared Inc. It covers the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter filing. The 2022 comparison reflects the accounting acquirer’s historical results following the October 2022 reverse merger.

Business context

Coeptis is a development-stage biopharmaceutical company focused on cell therapies and related technologies, including GEAR-NK, SNAP-CAR, unmodified natural killer cells and a CD38 diagnostic. Most programs remain preclinical; the acquired DVX201 programs include two Phase 1 studies. The company reported no sales or consulting revenue in either 2023 or 2022.

Financial performance and liquidity

MetricFY 2023FY 2022
Revenue$0$0
Operating expenses$21.49 million$34.20 million
Net loss$21.27 million$37.57 million
Loss per share, basic and diluted$0.83$2.63
Net cash used in operating activities$7.24 million$3.88 million
Cash at year-end$1.47 million$3.79 million
  • Gross margin is not meaningful because the company reported no revenue or cost of goods sold.
  • Current assets were $5.25 million and current liabilities were $2.99 million, implying working capital of approximately $2.26 million. Current assets included $3.50 million of notes receivable; collection and timing matter to liquidity.
  • Total liabilities were $3.76 million. Notes payable totaled $1.125 million, including $975,000 classified as current; the company also reported $557,250 of warrant liabilities. A $100,000 convertible note was in default at year-end.
  • Financing activities provided $4.92 million in 2023, while cash declined by $2.32 million. The filing reports no cash used in investing activities.

Changes versus 2022

  • Net loss narrowed by $16.31 million, primarily as operating expenses fell, including lower professional and strategic financing/merger-related costs. The comparison is affected by unusually high 2022 expenses and debt-related charges.
  • Research and development expense rose to $6.67 million from $20,887, including $4.94 million of Deverra transaction consideration expensed in 2023.
  • Operating cash use increased by $3.36 million despite the lower reported net loss, in part reflecting non-cash expenses and changes in working capital.
  • Cash fell to $1.47 million from $3.79 million. Shares outstanding increased to 35.33 million from 19.57 million during 2023, alongside equity issuances and acquisition-related stock consideration.

Outlook, risks and unusual items

  • Management said it expected no significant revenue for at least two years and anticipated continued losses and negative operating cash flow. Profitability depends on successful development, regulatory approval and commercialization or partnerships.
  • The auditor included a going-concern explanatory paragraph, citing recurring losses and insufficient working capital. Management expects to seek additional equity or debt financing; success and acceptable terms are not assured.
  • Management said year-end cash was expected to meet short-term needs through the first quarter of 2024 only if the company did not pursue strategic transactions. Subsequent to year-end, it borrowed $1.5 million under a note with a 10% original issue discount and 8% interest, payable April 15, 2024, subject to possible extension.
  • In August 2023, Coeptis licensed Deverra technology and acquired assets including two IND applications and two Phase 1 programs. Consideration included approximately $570,000 cash, 4.0 million shares and assumed trial liabilities; total consideration of $4.94 million was expensed. Further milestone and royalty payments may be triggered by development.
  • In 2023 financing transactions, the company issued equity and warrants and repriced certain June offering warrants from $1.65 to $1.36 per share. These instruments and outstanding warrants create potential dilution. September share sales included $2.5 million of promissory notes rather than cash proceeds.
  • Nasdaq notified the company on January 29, 2024 that its stock was below the $1.00 minimum bid-price requirement. The initial compliance period ran through July 29, 2024, subject to possible extension; delisting remains a risk.
  • Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023 due to material weaknesses in control design, segregation of duties, financial close and review. Remediation efforts were underway.
  • Other key risks include clinical and regulatory failure or delay, dependence on third-party collaborators and financing, intellectual-property protection, competition, and the ability to retain Nasdaq listing. Management reported no pending litigation expected to have a material adverse effect.

Investor verification priorities

  • Confirm current cash, cash runway and the status, terms and repayment of the January 2024 borrowing and other near-term debt maturities.
  • Assess the collectability and due dates of the $3.50 million year-end notes receivable, including the notes issued in connection with share transactions.
  • Track Nasdaq bid-price compliance and any extension, reverse split or delisting developments.
  • Review actual dilution from issued and outstanding shares, pre-funded warrants, Series A/B warrants and other equity awards.
  • Verify progress and funding needs for Deverra/DVX201, GEAR-NK, SNAP-CAR and CD38-Diagnostic programs, including regulatory and clinical milestones.
  • Monitor whether management remediates the disclosed control weaknesses and whether any subsequent filing identifies restatements or additional deficiencies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.